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Background: Obstructive sleep apnea syndrome (OSAS) is associated with cardio-
vascular morbidity and mortality. Elevated levels of serum homocysteine are also
associated with cardiovascular morbidity and mortality. We aimed to investigate
serum homocysteine levels and conventional cardiovascular risk factors (cholesterol,
low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides) in OSAS
patients with and without cardiovascular diseases (CVD).
Methods and Results: Levels of homocysteine, cholesterol, LDL, HDL and triglycer-
ides were measured in 114 obese, male participants after overnight fasting. The
presence of OSAS was determined by standard overnight polysomnography. The cases
included OSAS patients (apnea–hypopnea index: AHIX5) with CVD (OSAS+CVD group)
(n:25) and without CVD (OSASCVD group) (n:47). Control group was patients
without OSAS (AHIo5) with CVD (CVD group) (n:42). The serum homocysteine levels
were significant.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnea syndrome (OSAS), charac-
terized by repeated episodes of upper airways
obstruction during sleep leading to significant hypox-
emia, is a very prevalent disorder particularly among
middle-aged, obese men, although its existence in
women is increasingly recognized.1 EpidemiologicalElsevier Ltd. All rights reserv
2026119;
du.tr (T.U. Ciftci).studies estimate that 2–5% of the population meets
the minimal diagnostic criteria (snoring, witnessed
apnea and excessive daytime sleepiness), and two
community-based studies have found that about 2%
of women and 4% of men are affected by OSAS.2 The
syndrome is associated with cardiovascular morbid-
ity, such as systemic hypertension, coronary heart
disease, atherosclerosis, and stroke. Studies of
random samples obtained from the general popula-
tion suggest that the existence of OSAS constitute a
significant risk for cardiovascular diseases (CVD)
independently of other known risk factors.3–6ed.
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untreated sleep apnea are likely mechanisms that
produce functional and structural changes within
the cardiovascular system. Obesity, higher blood
pressure, and advancing age, which are common
characteristics of patients with OSAS, contribute to
the risk for CVD. Recent studies indicate that OSAS
is associated with or aggravates other risk factors
for CVD7 and one of these risk factors is hyperho-
mocysteinemia.
Homocysteine is an intermediate amino acid in
methionine–cysteine metabolism, as it represents a
branching point at which it can be remethylated to
methionine or converted to cysteine.8 It was
described by McCully,9 in infants with inborn errors
of metabolism, as an atherogenic compound that
accelerates atherosclerosis. Many clinical and
epidemiological studies confirmed this observation
that mild elevation in total plasma homocysteine
confers an increased risk for peripheral arterial
occlusive disease, coronary artery disease, and
cerebrovascular disease similar to other conven-
tional risk factors such as hyperlipidemia or
smoking.10,11
Pertaining to the associations between OSAS and
cardiovascular morbidity and between homocystei-
nemia and cardiovascular morbidity, we investi-
gated the serum levels of homocysteine and
conventional cardiovascular risk factors such as
total cholesterol, low-density lipoprotein (LDL),
high-density lipoprotein (HDL), very low-density of
lipoprotein (VLDL) and triglycerides in patients
diagnosed to have OSAS with and without CVD.
We compared them to control subjects with CVD
without OSAS.Materials and methods
Patients
Age and Body Mass Index (BMI) matched male
subjects were included in order to eliminate the
factors affecting CVD such as age, sex and obesity
in the present study. All patients were obese with
BMI427 kg/m2. Subjects were recruited from those
who were referred for suspected sleep apnea to our
Sleep Disorders Center, Gazi University, Faculty of
Medicine. The study was approved by the institu-
tional Ethics Committee, and study was performed
in accordance with the guidelines of declaration of
Helsinki. The control subjects and OSAS patients
were examined with polysomnography (PSG) and
classified according to data of the apnea–hypopnea
index (AHI). BMI was calculated as weight inkilograms divided by the square of the height in
meters measured by a scale. Patients with hyper-
tension (HT) and/or ischemic heart disease (IHD)
were enrolled as patients with CVD.
None of the patients has used folat or other food
supplements like it, but data about lipid lowering
medications of patients were not available.
Before enrollment, all subjects gave written
informed consent.
Sleep study
Overnight PSG was performed in all patients by a
computerized system (Somnostar alpha; Sensorme-
dics, USA) and included the following variables:
electrooculogram (two channels), electroencepha-
logram (four channels), electromyogram of sub-
mental muscles (two channels), electromyogram of
the anterior tibialis muscle of both legs (two
channels), and electrocardiogram and airflow (with
an oro-nasal thermistor). Chest and abdominal
efforts (two channels) were recorded using induc-
tive plethysmography, arterial oxyhemoglobin sa-
turation (SaO2: 1 channel) by pulse oximetry with a
finger probe. The recordings were conducted at a
paper speed of 10mm/s, and sleep stage were
scored according to the standard criteria of
Rechtschaffen and Kales.12 Arousals were scored
according to accepted definitions.13 Apneas were
defined as complete cessation of airflow X10 s.
Hypopneas were defined as reduction of 450% in
one of three respiratory signals, airflow signal or
either respiratory or abdominal signals of respira-
tory inductance plethysmography, or with a fall of
X3% in oxygen saturation or an arousal. The AHI
was defined as the number of apneas and hypop-
neas per hour of sleep. Patients with AHIo5 were
included in control group. Patients with AHIX5
were considered as OSAS.
Patients were divided into three groups:1. OSAS+CVD group: patients with OSAS and CVD
(HT and/or IHD)2. OSASCVD group: patients with OSAS without
CVD3. CVD group: patients without OSAS with CVD (HT
and/or IHD).
Circulating parameters assay
All subjects had fasting blood samples taken
between 07:00 AM and 08:00 AM. Blood samples
were immediately sent to the hospital laboratory.
Cholesterol and triglyceride concentrations in
serum and lipoprotein fractions were determined
enzymatically using standard laboratory proce-
dures. Serum homocysteine levels were measured
using Chromsystems HPLC with Agilent 1100 series
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as 5–14 mmol/L for homocysteine levels.Statistical analysis
Means and standard errors of measurement (SEM)
were determined for continuous variables and
percentage for categorical variables. The signifi-
cance of differences between three groups was
analyzed with the Kruskal–Wallis variance analysis.
Differences between two groups were analyzed
with the Mann–Whitney U test. We applied a
Bonferroni correction for multiple comparisons.
Categorical data were analyzed by x2 with Fisher
Exact Probability test. The correlation was ana-
lyzed with Spearman correlation coefficient.
To assess the relative strength of association of
OSAS as well as possible confounding factors with
homocysteine, we employed a multiple regression
analysis to the patients with OSAS as a single group.
In this analysis, we used serum levels of homo-
cysteine as dependent variable and evaluated the
order of inclusion in the model of the following
independent variables: AHI, BMI, total cholesterol,
HDL, LDL, and VLDL.
All statistical analyses were carried out using
statistical software (SPSS, version 11.0 for Win-
dows; SPSS Inc; Chicago, IL). Differences were
considered significant at Po0:05.Results
Newly diagnosed obese (BMI427 kg/m2) men with
OSAS and age- and BMI matched male control
subjects with HT and/or IHD were enrolled in
present study.Table 1 The demographic and clinical data of study gro
Mean7SD OSASCVD (n ¼ 47) OSAS
Age (years) 48.56710.02 51.
BMI (kg/m2) 30.5375.1 32.
AHI 32.93728.7 44.
Total cholesterol 218.47784.99 204
HDL 48.5717.87 46.
LDL 129.51741 113.
VLDL 29.48711.87 32.
Triglyceride 168.227123.44 172.
Homocysteine 14.774.52y 17
OSAS: obstructive sleep apnea syndrome; CVD: cardiovascular dise
high-density lipoprotein; LDL: low-density lipoprotein; VLDL: ver
Po0:001, OSASCVD group vs. CVD group and OSAS+CVD grou
yPo0:001, OSASCVD group vs. CVD group and OSAS+CVD grouAfter 157 obese, male subjects underwent PSG,
72 were considered to have OSAS, which included
25 patients with CVD and 47 patients without CVD.
Eighty-five subjects were considered not to have
OSAS and of these, 42 patients, who were with CVD,
were enrolled as control subjects. The 114 patients
were subdivided into three groups:1.ups
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p vsOSAS+CVD group: patients with OSAS and CVD
(HT and/or IHD) (n ¼ 25)2. OSASCVD group: patients with OSAS without
CVD (n ¼ 47)3. CVD group: patients without OSAS with CVD (HT
and/or IHD) (n ¼ 42).
The demographic and clinical data of the three
groups are presented in Table 1. The serum
homocysteine levels were significantly elevated in
OSAS+CVD group more than both the other two
groups (Po0:001). When differences between two
groups were analyzed, we showed that serum
homocysteine levels significantly increased more
in the OSASCVD group compared to the CVD
group (Table 1, Fig. 1). Hyperhomocysteinemia
(414 mmol/L) was found in 17 patients (68%) of
OSAS+CVD group, in 22 patients (46.8%) of
OSASCVD group and in seven (16.7%) of CVD
group. Therefore, hyperhomocysteinemia was
found highest in OSAS+CVD groups (Po0:05). No
significant difference was detected among the
different groups with regard to serum total
cholesterol, HDL, LDL, VLDL and triglyceride levels
(Table 1).
When we evaluated the association between the
serum homocysteine level and AHI as a severity
measure of OSAS, homocysteine levels were posi-
tively correlated with the severity of OSAS both in
OSAS+CVD (r ¼ 0:73, Po0:001) and OSASCVD.
VD (n ¼ 25) CVD (n ¼ 42) P-value
8.67 48.86711.55 40.05
4.89 27.1774.09 40.05
41.53 2.1171.56 o0.001
65.18 197.37739.45 40.05
8.69 47.26710.4 40.05
28.3 122.42735.59 40.05
18.69 29.36716.1 40.05
121.78 154.92797.64 40.05
6.58y 10.3573.63 o0.001
; BMI: body mass index; AHI: apnea–hypopnea index; HDL:
w-density lipoprotein; SD: standart deviation.
s. CVD group.
. CVD group.
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tion between serum lipid and homocysteine levels
in all groups.
Evaluation of the relative strength of association
using multiple regression analysis between homo-
cysteine and OSAS severity as well as the other
possible confounding variables showed that homo-
cysteine levels were independently associated with
OSAS severity both in OSAS+CVD (F ¼ 3:1, Po0:05)
and OSASCVD group (F ¼ 1:7, Po0:005).H
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Figure 1 Serum homocysteine levels in the study groups.Discussion
The acute hemodynamic alterations of obstructive
sleep apnea include systemic and pulmonary
hypertension, increased right and left ventricular
afterload, and increased cardiac output. Earlier
reports attributed the coexistence of OSAS with
CVD to the shared risk factors such as age, sex, and
obesity. However, recent epidemiologic data con-
firm an independent association between OSAS and
the different manifestations of CVD. Possible
mechanisms may include a combination of inter-
mittent hypoxia and hypercapnia, repeated arou-
sals, sustained increase in sympathetic tone,
reduced baroreflex sensitivity, increased platelet
aggregation, elevated plasma fibrinogen levels and
also hyperhomocysteinemia.14
Pertaining to the associations between OSAS and
cardiovascular morbidity and between homocystei-
nemia and cardiovascular morbidity, our study
confirms the previous finding by Lavie et al.15,16
that levels of homocysteine are elevated in OSAS
patients. The most important difference in our
study is that it consists of obese males with
completely similar age and weights. Therefore,
some parameters affecting cardiovascular morbid-
ity such as sex, age and BMI has been eliminated in
this study. In Lavie’s study, however, age and BMI
have been differed between groups.
We showed that OSAS patients with and with-
out CVD had significantly higher levels of homo-
cysteine when compared with patients with
CVD without OSAS, and serum homocysteine levelsH
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OSAS. There was no difference in conventional risk
factors for CVD among the three groups, but there
was also a limitation in our study because we had
no data about lipid lowering medications of
patients. Therefore, the indifference between
groups may be explained by decreasing high lipid
levels of some patients with medication.
We found that only 16.6% of CVD group had
hyperhomocysteinemia (414 mmol/L) and the
mean homocysteine levels in CVD group was
10.3573.63 mmol/L. This mean value is similar to
the level of homocysteine observed in seven studies
investigating large groups of cardiovascular pa-
tients (12.271.3 mmol/L)17 and in Lavie’s study
investigating patients with IHD (11.9275.77 mmol/
L).15 Our CVD group contained both HT and IHD
patients. Although it is known to increase in CVD
morbidity by hyperhomocysteinemia, considering
the other factors also affecting CVD, it would not
be surprising to find low homocysteine levels in this
CVD group.
In patients with OSAS and CVD, serum homo-
cysteine levels were higher than patients with CVD
without OSAS. Besides, in OSAS patients with CVD,
the number of patients whose homocysteine levels
were above the limits was found to be significantly
higher. This suggests that, among CVD patients,
patients with OSAS may have higher homocysteine-
mia due to OSAS. The essential issue deserving to
be researched is the mechanism that is responsible
for the increased serum homocysteine levels in
OSAS.
In patients with OSAS, cyclical alterations of
arterial oxygen saturation are observed with oxy-
gen desaturation developing in response to apnea
followed by the resumption of oxygen saturation
during hyperventilation. This phenomenon has
been referred to as hypoxia/reoxygenation and
might alter the oxidative balance through the
induction of excess oxygen free radicals quite like
in the sequelae of ischemia/reperfusion injury.
Some authors have reported that systemic biomar-
kers of oxidative stress has increased in patients
with sleep apnea suggesting a possible role in the
pathologic consequences of OSAS.18 Excess super-
oxide production due to hypoxia/reoxygenation
may also inactivate nitric oxide resulting in the
formation of the toxic peroxynitrite. This may
further prevent the inactivation of homocysteine
leading to an increase in its levels, putting OSAS
patients with cardiovascular morbidity at a greater
risk.16
Endothelial dysfunction, which is the first step in
the development of atherosclerosis according to
the response to injury hypothesis, was initiallyimplicated with hypercholesterolemia. However,
endothelial dysfunction could result from many
seemingly unrelated pathological conditions such
as increased plasma homocysteine levels. Cumula-
tive data in vivo and in vitro clearly demonstrate
that homocysteine affects multiple vascular func-
tions such as promoting a prothrombotic phenotype
of the endothelium by increasing platelet aggrega-
tion and activation, and stimulating vascular
smooth muscle cell proliferation. Currently, the
leading mechanisms proposed for the adverse
effects of homocysteine on endothelial function
implicate oxidative stress and depletion in nitric
oxide bioavaliability.11,16,19
In conclusion, the impact of alleviating OSAS on
cardiovascular risk factors such as hyperhomocys-
teinemia has not been fully elucidated. Given the
compelling epidemiological and mechanistic evi-
dence implicating increased homocysteine in CVD,
homocysteine may be an important factor linking
OSAS to cardiovascular morbidity.
Since CPAP is a very efficient treatment method
which eliminates the oxygen desaturation and
other consequences resulting from obstructive
respiratory events, we speculate that CPAP-related
improvement in OSAS also translates into lower
serum homocysteine level and, by inference, a
decrease in cardiovascular risk. Further studies are
needed to evaluate the effect of CPAP on the serum
homocysteine levels.References
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